You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Around the Region

Elan moves to block takeover bid

DUBLIN — Irish drug maker Elan Corp. said Monday that it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis drug Tysabri.

Analysts said the offer, contingent on Elan’s pending sale of its Tysabri rights to partner Biogen Idec Inc., was designed to deter shareholders from considering a takeover bid by Royal Pharma.

Continue reading below

Elan said it planned to pay shareholders 20 percent of its Tysabri royalties received from Biogen Idec twice annually beginning in the fourth quarter this year.

Elan and Biogen Idec, based in Weston, Mass., jointly developed Tysabri and have split earnings since the drug’s launch in the US market in 2004.

Last month Elan agreed to sell its interest in Tysabri to Biogen Idec for $3.25 billion in cash and recurring royalty payments.

Royal Pharma launched a $6.5 billion bid for Elan on Feb. 25 that values the Dublin-based company at approximately $11 a share.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of